Remove Bioinformatics Remove Protein Expression Remove Research
article thumbnail

Hsa?miR?503?5p regulates CTDSPL to accelerate cisplatin resistance and angiogenesis of lung adenocarcinoma cells

Chemical Biology and Drug Design

Hsa-miR-503-5p expression in LUAD and the target gene downstream of hsa-miR-503-5p was predicted by bioinformatics analysis. The results showed that hsa-miR-503-5p showed high expression, while its target gene CTDSPL presented decreased expression in LUAD.

article thumbnail

Hederagenin inhibits high glucose?induced fibrosis in human renal cells by suppression of NLRP3 inflammasome activation through reducing cathepsin B expression

Chemical Biology and Drug Design

Hederagenin attenuated HG-induced increase in mRNA and protein expression of NLRP3, ASC, and IL-1β. Bioinformatics analysis predicted cathepsin B (CTSB) as a target of hederagenin to modulate NOD-like receptor (NLR) pathway. Hederagenin also suppressed HG-induced increase in mRNA and secretion levels of FN, Col.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Plumbagin induces apoptosis, cell cycle arrest, and inhibits protein synthesis in LoVo colon cancer cells: A proteomic analysis

Chemical Biology and Drug Design

A label-free proteomics technology was employed to investigate alterations in protein expression in LoVo cells treated with plumbagin. The LC-MS/MS proteomics assay revealed 78 proteins that were differentially expressed upon treatment with plumbagin.

article thumbnail

Breaking Barriers in Solid Tumor Research: Precision Medicine & Strategic Operations

Conversations in Drug Development Trends

Solid tumors present a significant challenge to clinical research due to their complex and heterogeneous nature. Proactively Address Key Recruitment Challenges in Solid Tumor Clinical Research Solid tumor clinical research is challenging, especially because of tumor heterogeneity.